Trial Profile

An observational study of tasimelteon [HETLIOZ] in patients with Smith-Magenis Syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tasimelteon (Primary)
Indications Developmental disabilities; Sleep disorders
Focus Therapeutic Use

Most Recent Events

06 Nov 2024 According to Vanda Pharmaceuticals media release,European Medicines Agency action on Marketing Authorization Application for HETLIOZ and HETLIOZ LQ for Smith-Magenis Syndrome is expected in the first quarter of 2025.
26 Feb 2015 New trial record
19 Feb 2015 According to media release, results of this trial are expected in first half of 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com